LAA

Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer

Retrieved on: 
Monday, March 25, 2024
Mechanical, SAS, American Heart Association, Percutaneous aortic valve replacement, Product marketing, Abbott Laboratories, Massachusetts Institute of Technology, Business, Patient, Business development, LAA, Medtronic, MD, Senior, Master, Retirement, TAVR, Marketing, Management

Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO).

Key Points: 
  • Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO).
  • In conjunction with this, and following eight years at the helm of the business, Helmut Straubinger is retiring as President & CEO.
  • Ahmed Elmouelhi is a seasoned professional with more than 20 years of medical device experience across strategy, sales and marketing, R&D, and clinical science.
  • Before joining TRiCares, Ahmed served as the Senior Vice President of Product Marketing, Strategy, and Business Development at AtriCure.

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, March 26, 2024
Hospitals, Health, Cardiology, Medical Devices, Atrial fibrillation, Conference, Interest, LAA

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
  • AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 1:30 p.m. Eastern Standard Time.
  • Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com .

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, International, Atrial fibrillation, Investment, Growth, GAAP, Webcast, Patient, LAA, Research, Video game

On a sequential basis, worldwide revenue for the fourth quarter 2023 increased approximately 8.4% over third quarter 2023.

Key Points: 
  • On a sequential basis, worldwide revenue for the fourth quarter 2023 increased approximately 8.4% over third quarter 2023.
  • Gross profit for the fourth quarter 2023 was $79.8 million compared to $65.1 million for the fourth quarter 2022.
  • Adjusted EBITDA was positive for the fourth quarter 2023 at $4.8 million, compared to positive $6.0 million for fourth quarter of 2022.
  • Adjusted loss per share for the fourth quarter 2023 was $0.21 compared to $0.09 for the fourth quarter 2022.

AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference

Retrieved on: 
Thursday, January 25, 2024
Hospitals, Health, Cardiology, Medical Devices, LAA, Digital health, Atrial fibrillation, Conference

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.
  • AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, February 15, 2024, to discuss its fourth quarter and full year 2023 financial results.
  • Those interested in listening to the conference call should register online using this link .
  • AtriCure’s management is also scheduled to host investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024, in Snowbird, Utah.

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024

Retrieved on: 
Monday, January 8, 2024
Hospitals, Health, Cardiology, Medical Devices, Growth, Patient, LAA, Atrial fibrillation, GAAP

Preliminary, unaudited revenue for fourth quarter 2023 is expected to be $106.5 million, reflecting growth of approximately 21% over the fourth quarter of 2022 (20% on a constant currency basis).

Key Points: 
  • Preliminary, unaudited revenue for fourth quarter 2023 is expected to be $106.5 million, reflecting growth of approximately 21% over the fourth quarter of 2022 (20% on a constant currency basis).
  • Fourth quarter revenue was driven by strong growth in Hybrid AF™ therapy, followed by sales of our AtriClip®, Encompass®, and cryoSPHERE® devices.
  • “Our fourth quarter 2023 results complete an exceptional year at AtriCure, as we extend our impact on patients globally,” said Michael Carrel, President and Chief Executive Officer of AtriCure.
  • Management also projects full year 2024 positive adjusted EBITDA of approximately $26 million to $29 million, with improvements annually thereafter.

AtriCure Appoints Shlomi Nachman to the Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, Johnson & Johnson, Electrophysiology, Research, Chemistry, LAA, Medical device, Ear, Face, Growth, Optometry, Patient, Safety, Pharmaceutical industry

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors.

Key Points: 
  • AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors.
  • Prior to that, Mr. Nachman served in various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis.
  • “I am thrilled to be joining the AtriCure Board during this exciting time of accelerating growth and profitability,” said Mr. Nachman.
  • I have done extensive diligence on the company’s business, prospects, and end user markets, and believe them to be significantly underpenetrated.

AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 20, 2023
FDA, Medical Devices, Hospitals, Health, Cardiology, Conference, LAA, Atrial fibrillation, Interest

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.
  • AtriCure’s management is scheduled to present on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Standard Time.
  • Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com .

Johnson & Johnson MedTech Acquires Laminar, Inc.

Retrieved on: 
Thursday, November 30, 2023
Health, Surgery, Cardiology, Medical Devices, Acquisition, Research, Johnson & Johnson, LAA, Risk, Patient, Arrhythmia, Thrombosis, EPS, Heart, FDA, Electrophysiology, Atrial fibrillation, Stroke, Pharmaceutical industry, Laminar, Ventricular fibrillation

Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

Key Points: 
  • Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).
  • Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond.
  • Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment.
  • “We are looking forward to advancing this vision as part of Johnson & Johnson MedTech.”
    “We are excited to welcome Laminar to Johnson & Johnson MedTech,” said Jasmina Brooks, President, Biosense Webster.